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SDS-PAGE and immunoblotting
Intact and enzyme-digested human cartilage aggrecan and brain tissue homogenates were resolved by either SDS-PAGE (3-8% gradient gels) or agarose gel electrophoresis (1.2% gels; [35] [40] , with the predominant isoforms having a 240-260 kD core protein, whereas two lower mobility bands of more glycosylated aggrecan variants were disclosed at about 400 and 600 kD (Fig. 1A) . Antibodies 5G2, 8E10 and 4F8, that were found to recognize the C-terminal portion of the molecule, also detected proteolytic fragments of aggrecan that weakly entered the 3% gel in the undigested form and had a Mr~900-1000 kD (Fig. 1A) .
RNA extraction and RT-PCR
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* Antibody reactivity was examined in parallel by combined solid-phase binding assays (ELISA and dot-blotting, following membrane immobilization of the antigen) and Western blotting. † Trypsin-digested aggrecan, deprived of its chondroitin and keratan sulphate chains, was immunoblotted following SDS-PAGE under both reducing and non-reducing conditions and the cumulative data are reported; 'ϩ' indicates that immunoreactivity was completely eliminated following digestion, whereas Mrs corresponds to the sizes of the tryptic fragments recognized in Western blotting by the given antibodies. † † These antibodies were found to cross-react to a variable extent with bovine nasal cartilage and bovine sclera aggrecans, but not with rat chondrosarcoma, chick epiphysial, shark or whale aggrecans; cross-reactivity levels were determined by solid-phase binding assays using human aggrecan as reference and are arbitrarily scored as follows: '-', no cross-reactivity; 'ϩ', 25-50%; 'ϩϩ', 50-75%; 'ϩϩϩ' and 75-100% cross-reactivity. § These antibodies were found to react in solid-phase binding assays with a recombinant eukaryotic fragment corresponding to an N-terminal fragment encompassing the G1 and G2 globules interspaced by the inter-globular domain-1 (G1-IGD-G2). ¶ These antibodies were found to react in solid-phase binding assays with a recombinant eukaryotic fragment corresponding to the C-terminal lectin-like module of the G3 globular domain. $ The putative conformational nature of the epitopes was deduced by solid-phase binding assays and Western blotting involving prior reduction and alkylation (DTT/iodoacetamide) of chondroitinase-endo-␤-galactosidase-digested aggrecan preparations. ** The epitope recognized by these antibodies is presumed to reside at the GAG core protein linkage region (GlcA-␤ 1-3Gal-␤1-3Gal-␤1-4Xyl-␤1-O-Ser), as determined by solid-phase binding and competition assays using hexasaccharide peptides of this region.
Fig. 1 (A) Immunoblotting pattern observed with the panel of anti-aggrecan antibodies and highlighting the structural diversity of aggrecan variants revealed by the antibodies in aggrecan preparations from human adult articular cartilage. Aggrecan variants purified from healthy cartilage were sequentially digested with chondroitinase ABC, endo-␤-galactosidase and keratanase I, resolved by SDS-PAGE on 3-8% gradient gels under non-reducing conditions, blotted onto nitrocellulose and detected with the indicated antibodies. Mrs ranges reported on the right correspond to those previously identified by biochemical means in cartilage and including naturally occurring proteolytic fragments of the fully glycanated forms of the PG. A 900 kD Mr indication was extrapolated from the relative Mrs of bovine thyroglobulin and the unreduced laminin-1-nidogen complex from EHS. (B) Relative levels of immunoreactivity of different antibodies determined by solidphase binding assays involving immobilized human cartilage aggrecan that was digested in situ or
Immunoreactive (Fig. 1B) (Fig. S1A-E) . Conversely, tenascins-C and -R, which are also established PNN components in developing and adult rodent brains, were found to be poorly expressed in the adult human cerebral cortex PNNs; some tenascin-C was restricted to the ECM of subcortical white matter, whereas tenascin-R was diffusely expressed in the cortical ECM but not in the PNNs (Fig. S2A, B, D) . Unlike the situation in normal cortex, both tenascins were strongly expressed in the interstitial and perivascular compartments of glioblastoma lesions which were adopted as reference tissues (Fig. S2C, E) . (Fig. 2) . (Fig. 3C) [34] , revealed that in human adult brain keratan sulphates were diffusely distributed through the ECM, but were largely absent in PNNs (Fig. 4J) 
traits of the antibodies were further determined by immunochemical assays involving differential enzyme digestions combined with chemical treatments for partial or complete removal of glycan moieties. Antibody reactivity was found to be entirely unaffected by digestions with endo-and exoglycosidases, fucosidases, neuraminidases and hyaluronidases (not shown), but was differentially affected by digestions with chondroitinase ABC, keratanase I and II and endo-␤-galactosidase
Morphological and molecular verification of the integrity of post-mortem adult brain PNNs
Human brain expresses alternatively spliced forms of aggrecan
Differential aggrecan isoform deposition in PNNs and cortical ECM
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Fig. 3 (A) Topographical representation and (B) semi-quantitative evaluation of aggrecan isoform distribution in the different layers of Brodmann's area 6 in the human cerebral cortex (**, P Ͻ 0.05; #, P Ͻ 0.01). (C) Immunoblotting of whole brain homogenates with the indicated antibodies following sequential digestion of the lysate with chondroitinase ABC, endo-␤-galactosidase and keratanase I, SDS-PAGE on 5-15% gradient gels under non-reducing conditions, and transfer onto nitrocellulose membranes.
Fig. 4 (A-I) Overview of 9 aggrecan isoforms detected in the ECM and PNNs of cortical layer V of Brodmann's area 6, representative of the previously defined clusters: cluster 1, isoforms 5D3 and 7D4 (A, B), cluster 2, 7C9 and 3C7 (C, D), cluster 3, 5F12 and 5G5 (E, F), cluster 4, 5G2 and 2G5 (G, H), cluster 5, 8E10 (I). Keratan sulphate-bearing PGs are only detected in the neuropil ECM (J). Counterstaining with haematoxylin.
Magnification bar: 100 m.
Fig. 5 Global view of aggrecan deposition in Brodmann's area 6 as determined by staining with antibody 5D3. No aggrecan deposition could be observed in the neuropil ECM of cortical layer I (A, B), whereas a progressively increased expression of the PG could be noted starting from the deeper regions of cortical layer II and spanning Brodmann's entire area up to cortical layer VI (A, C-G). Aggrecan-containing PNNs are observed in association with small-medium sized neurons of cortical layers III-VI (A, C-G) and larger neurons of cortical layers V and VI (E-G). High magnification views of the cortical layers containing aggrecan-rich PNNs show aggrecan deposits surrounding both the neuronal cell bodies and the extended processes (C-G). Counterstaining with haematoxylin. Magnification bars: (A) 400 m; (B-G)
, 100 m. (Fig. S3A, B) . A lower number of PNNs were revealed by antibodies from cluster-3 and all of these were also detected by cluster-1 antibodies (Fig. S3C, D) . (Fig. 5A, C-G) . Aggrecancontaining PNNs were also revealed around a few smaller interneurons of cortical layer II (Fig. 5A and C) and more evidently around numerous small-to medium-sized polymorphous interneurons of cortical layers III. Within the same layer, although less evident, aggrecan enriched PNNs were also observed to be associated with small-to medium-sized pyramidal cells (Fig. 5A,  C and D) . In cortical layer IV, only smaller interneurons appeared to be sparsely decorated by aggrecan-containing PNNs (Fig. 5A  and D) , whereas within cortical layer V these PNNs were detected around numerous small-to medium-sized sized polymorphous interneurons and a few medium-sized pyramidal neurons (Fig. 5A  and E) 
clusters. Isoforms of clusters-1 and -2 almost totally coincided in the same PNNs, although a larger number of PNNs had isoforms recognized by antibody 5D3
Finally, the few weakly reactive PNNs revealed by antibodies recognizing aggrecan isoforms of cluster 4 were always present also on sections stained by cluster-1 antibodies (Fig. S3E, F). These results demonstrated that aggrecan isoforms from clusters-2 to -4 contributed differently to the PNNs characterized by cluster-1 isoforms, which in turn showed the widest molecular variation. The aggrecan isoform(s) recognized by antibody 5D3 and pertaining to cluster-1 was unique in that it was weakly expressed in laryngeal cartilage, but appeared abundant in brain (Table 2). We therefore investigated in more detail the distribution of this putative isoform(s). It was found to be virtually absent in both PNNs and ECM of cortical layer I (Fig. 5A and B) and widespread in PNNs and ECM of cortical layers II-VI. This aggrecan isoform distinctly revealed PNNs associated with numerous cortical interneurons and a restricted number of pyramidal cells. The ECM encompassing this isoform initiated at the boundary between cortical layers II and III and was progressively intensified in the deeper cortical layers, with a peak seen in cortical layer V
) and antibody 5D3 (D-F). Lectin WFA-stained PNNs are co-labelled by antibody 5D3 (arrowheads in A-C), (B) whereas other PNNs are labelled to different degrees only by antibody 5D3 (arrows, in B and C). Also note, at higher magnification, a double-stained polymorphous interneuron (inset in A-C) and the lectin WFA-stained cortical blood microvessels (A, C). (D-F) Reference aggrecan and our aggrecan 5D3 co-label a number of PNNs (arrowheads), whereas other PNNs are only stained by 5D3 (arrows in E and F). Counterstaining with the nuclear tracer TO-PRO-3.
Magnification bars: 100 m. (Fig. 5A, F and G (Fig. 6A-F (Fig. 8A) . Views of single optical planes revealed the finer details of synaptophysin-containing boutons regularly alternated with aggrecan deposits around neuronal cell bodies and processes (Fig. 8B-D) . Sections double-labelled with antibodies 5D3 and anti-GFAP highlighted an intricate pattern of astrocyte processes surrounding the neurons provided with aggrecan-rich PNNs (Fig. 8E) and terminating on the surfaces of these neurons, in close contact with the aggrecan deposits (Fig. 8F-H) . Thus, aggrecan-containing matrices seemed to be interposed between neuronal processes, astrocytic processes and their terminals in contact with cell somas.
interneurons, as well as clusters of larger, polymorphous interneurons
Detailed analysis of aggrecan-containing PNNs and their relationships with synaptic boutons and astrocytic processes
To unveil the detailed features of aggrecan-containing PNNs, their precise spatial arrangement and their connections with nerve terminals and glial cell processes, we carried out a high-resolution laser confocal microscopical analysis on thicker vibratome sections single-and double-labelled with antibody 5D3 and antibodies to synaptophysin or GFAP. Through this approach we were able to confirm the lack of significant deposition of aggrecan isoform(s) detected by antibody 5D3 in cortical layer I. Conversely, a greater number of finer 5D3-aggrecan PNNs interspaced between denser ones was highlighted throughout cortical layers II-VI, in which aggrecan-decorated neuronal processes were also evident at considerable distances from the neuronal cell bodies from which they originated (Fig. 7A-E). Additional peculiar traits of aggrecan-containing PNNs were observed around the cell body of medium-large sized polymorphous interneurons of layers V and VI. In fact, some of these neurons appeared to be surrounded by aggrecan deposits forming a continuous 'coat' rather than exhibiting the typical PNN mesh-like appearance (Fig. 7C and F-K). Comprehensive images of the complete aggrecan-containing neuronal envelope were obtained by analysing both single optical planes and three-dimensional reconstructions of confocal projections, stacks of single optical planes (Figs. 7G and S4; Movie S1). Through these it was possible to reveal a honeycomb-like deposition of the aggrecan matrix around and along the dense PNN coating, suggestive of aggrecan containing boundaries of ECM encompassing pre-terminal nerve fibres (Figs. 7C, F-K and S4; Movie S2). These analyses further highlighted the presence of perineuronal satellite cells completely embedded within the aggrecan 'coat' (Figs. 7F, I-K and S4 and S5; Movies S1 and S2). Detailed analysis of thicker sections double-labelled with antibody 5D3 and antibodies to synaptophysin -an integral membrane glycoprotein of the synaptic vesicles -demonstrated a number of synaptic boutons in contact with the aggrecan-containing PNNs
Differential association of aggrecan-containing PNNs with distinct classes of cerebral cortical neurons
We next sought to better characterize the classes of cortical neurons surrounded by aggrecan-containing PNNs. To this end, we employed a similar laser confocal microscopic approach, in this case entailing double immunolabelling of the sections with antibody 5D3 and either antibodies to the neurotransmitter Glu, Magnification bars: A, B, 100 m; C-F, 20 m; G-K, 10 (Fig. 9A-C) , whereas on the same area 28.8% Ϯ
6.9% of interneurons, revealed by their reactivity for Ca 2ϩ
BPs, had these PNNs (Fig. 9D-F) . Subsequently, the subclasses of cortical interneurons with associated aggrecan nets were revealed by double immunolabellings with antibody 5D3 and the individual interneuron markers parvalbumin, calbindin and calretinin. In cortical layer III, aggrecan-containing PNNs were consistently associated with parvalbumin-expressing interneurons (Fig. 10A) , whereas a few parvalbumin interneurons showed faint aggrecan PNNs in layers V and VI, while aggrecan deposits appeared to be only rarely associated with these neurons in layers II and IV. The total percentage of parvalbumin-positive interneurons associated with aggrecan-rich PNNs was estimated to be 65.0% Ϯ 8.8% (Fig. 10B) . A smaller fraction of calbindin-positive neurons was associated with aggrecan-containing PNNs in layers II and III (11.2 Ϯ 4.4%; Fig. 10C and D) . Finally, aggrecan-rich PNNs were never seen in association with calretinin-expressing interneurons residing within the different cortical layers (Fig. 10E and F) .
Fig. 8 Confocal laser microscopy images of sections through Brodmann's area 6 double-labelled for aggrecan with antibody 5D3 and synaptophysin (A-D) or GFAP (E-H). (A-D) On the projection image (A), aggrecan meshes and nerve terminals are tightly intermingled on the neuronal soma and dendrite surfaces. (B-D) show single optical planes of (A) highlighting details of aggrecan-deposits close to synaptic boutons on the primary dendrite (B; arrows in C) and cell soma (arrows in D). (E-H) On the projection image (E), the GFAP ϩ astrocyte processes form a dense perineuronal network which penetrates the aggrecan-rich PNN; (F-H) show single optical planes of (E) evidencing processes in close contact with the aggrecan envelope (arrows). Counterstaining with the nuclear marker TO-PRO-3. Magnification bars:
Discussion
PNNs have recently been demonstrated to contribute to the stabilization of synaptic contacts during critical periods of brain development [7, [43] [44] [45] [46] [44, [52] [53] [54] . The relative distribution of PGs in PNNs is therefore a subject of particular interest and has been previously investigated in a wealth of animal species, including chick, mouse, rat and cat [18-20, 22, 55-58] . Detailed information is also available concerning the glycan composition of PNNs in the rat CNS [23, 33, 59, 60] [26, 32] . Aggrecan expression has also been documented in the mammalian CNS, where it has been suggested to be linked to different classes of neurons [12, 17, 22, 23, 31, 33, [61] [62] [63] [17, 33, 43, 64] , and significant information about the expression pattern of these lecticans in rodent CNS has also been obtained [23, 33] . However, although previous in situ hybridizations have highlighted aggrecan transcription in mammalian CNS neurons [33] [49, 72] , and PNNs appear to be altered in some neurological diseases [73] . It 
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Tenascin-C is not found in the cortex (A), but shows diffuse staining in white matter ECM (B). For comparison, the glycoprotein is found to be abundantly expressed by neoplastic cells and neovascular structures of malignant glioblastoma lesions (C). Some tenascin-R can be seen in the cortex (D), but its expression is significantly poorer than in glioblastoma lesions (E). Counterstaining with haematoxylin. Magnification bars:
A-E: 75 m. 
